Demographic features | Value |
Male/female, n | 6/78 |
Mean age ± SD (years) | 41.3 ± 12.2 |
Mean disease duration ± SD (months) | 142.1 ± 103.8 |
Clinical manifestations, n (%) | |
Joint involvement | 57 (67.8) |
Skin involvement | 58 (69.0) |
Serositis | 18 (21.4) |
Hematological manifestations | 37 (44.0) |
Neuropsychiatric involvement | 10 (11.9) |
Renal involvement | 31 (36.9) |
Laboratory manifestations, n (%) | |
Antinuclear antibodies | 84 (100.0) |
Anti-DNA | 69 (82.1) |
Anti-Sm | 13 (15.5) |
Anti-SSA | 24 (28.6) |
Anti-SSB | 10 (11.9) |
Anti-RNP | 10 (11.9) |
Anti-cardiolipin IgG/IgM | 30 (35.7) |
Anti-β2Glicoprotein I IgG/IgM | 8 (9.5) |
Lupus anticoagulant | 12 (14.3) |
Low C3 levels | 32 (38.1) |
Low C4 levels | 44 (52.4) |
Treatments, n (%) | |
Corticosteroids | 60 (71.4) |
Hydroxychloroquine | 54 (64.3) |
Cyclosporine A | 19 (22.6) |
Methotrexate | 17 (20.2) |
Cyclophosphamide | 19 (22.6) |
Mycophenolate mofetil | 15 (17.8) |
Azathioprine | 18 (21.4) |
ASA | 25 (29.7) |
Anticoagulant therapy | 9 (10.7) |